Literature DB >> 17252273

Antibody response in mice infected with Mesocestoides vogae (syn. Mesocestoides corti) tetrathyridia after treatment with praziquantel and liposomised glucan.

Gabriela Hrckova1, Samuel Velebný, Grigorij Kogan.   

Abstract

The therapeutic effect of praziquantel (PZQ) involves synergy with the humoral immune response during helminth infections, which is modulated by parasitic antigens. During experimental murine infections with the larval stage of cestoda Mesocestoides vogae (syn. M. corti), dynamic changes in the IgG and IgM antibody serum levels to both soluble somatic and secretory larval antigens were investigated after administration of PZQ alone and after its co-administration with the immunomodulator (l-->3)-beta-D-glucan entrapped in liposomes (lip.glucan). During the 2 weeks of follow-up after termination of therapy, specific IgG and IgM serum levels to the somatic antigens (enzyme-linked immunosorbent assay test) significantly decreased, whereas concentrations of the antibodies to the secretory antigens moderately increased, both in comparison with the control. Moreover, the number of immunogenic larval antigens (analysed by Western blot) was higher after combined therapy in comparison with single drug administration, which correlated with the intensity of reduction of the larval counts in the liver and peritoneal cavity of mice. Our data showed that administration of PZQ alone and in combination with lip.glucan resulted in marked changes in the dynamics of IgG and IgM antibodies to the somatic larval antigens, which were probably induced by the newly exposed antigens. In this respect, glucan can enhance chemotherapeutic activity of PZQ against larval cestodes by means of stimulation of the macrophage/monocyte effector functions, which seemed to contribute to the more intense larval damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17252273     DOI: 10.1007/s00436-006-0434-2

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  34 in total

1.  ASEXUAL MULTIPLICATION OF MESOCESTOIDES TETRATHYRIDIA IN LABORATORY ANIMALS.

Authors:  D SPECHT; M VOGE
Journal:  J Parasitol       Date:  1965-04       Impact factor: 1.276

2.  Beneficial effect of enhanced macrophage function in the trauma patient.

Authors:  W Browder; D Williams; H Pretus; G Olivero; F Enrichens; P Mao; A Franchello
Journal:  Ann Surg       Date:  1990-05       Impact factor: 12.969

3.  Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice.

Authors:  A A Sabah; C Fletcher; G Webbe; M J Doenhoff
Journal:  Exp Parasitol       Date:  1985-12       Impact factor: 2.011

4.  Effect of praziquantel and liposome-incorporated praziquantel on peritoneal macrophage activation in mice infected with Mesocestoides corti tetrathyridia (Cestoda).

Authors:  G Hrckova; S Velebny
Journal:  Parasitology       Date:  1997-05       Impact factor: 3.234

5.  Altered behaviour of carbohydrate-bound molecules and lipids in areas of the tegument of adult Schistosoma mansoni worms damaged by praziquantel.

Authors:  S F Lima; L Q Vieira; A Harder; J R Kusel
Journal:  Parasitology       Date:  1994-11       Impact factor: 3.234

6.  Treatment of Toxocara canis infections in mice with liposome-incorporated benzimidazole carbamates and immunomodulator glucan.

Authors:  G Hrckova; S Velebný
Journal:  J Helminthol       Date:  2001-06       Impact factor: 2.170

7.  Glucans exhibit weak antioxidant activity, but stimulate macrophage free radical activity.

Authors:  E Tsiapali; S Whaley; J Kalbfleisch; H E Ensley; I W Browder; D L Williams
Journal:  Free Radic Biol Med       Date:  2001-02-15       Impact factor: 7.376

8.  Immunorestorative effect of glucan immunomodulator on guinea pigs with experimental ascariosis.

Authors:  J Soltýs; M Benková; Z Borosková
Journal:  Vet Immunol Immunopathol       Date:  1994-09       Impact factor: 2.046

9.  Praziquantel and liposomized glucan-treatment modulated liver fibrogenesis and mastocytosis in mice infected with Mesocestoides vogae (M. corti, Cestoda) tetrathyridia.

Authors:  G Hrckova; S Velebný; Z Daxnerová; P Solár
Journal:  Parasitology       Date:  2006-04       Impact factor: 3.234

10.  Overview of (1-->3)-beta-D-glucan immunobiology.

Authors:  D L Williams
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

View more
  5 in total

1.  Proteomic Analysis of Excretory-Secretory Products of Mesocestoides corti Metacestodes Reveals Potential Suppressors of Dendritic Cell Functions.

Authors:  Emilia Vendelova; Jeferson Camargo de Lima; Karina Rodrigues Lorenzatto; Karina Mariante Monteiro; Thomas Mueller; Jyotishman Veepaschit; Clemens Grimm; Klaus Brehm; Gabriela Hrčková; Manfred B Lutz; Henrique B Ferreira; Justin Komguep Nono
Journal:  PLoS Negl Trop Dis       Date:  2016-10-13

2.  Clinical forms of peritoneal larval cestodiasis by Mesocestoides spp. in dogs: diagnosis, treatment and long term follow-up.

Authors:  Silvia Carta; Andrea Corda; Claudia Tamponi; Giorgia Dessì; Francesca Nonnis; Laura Tilocca; Agostina Cotza; Stephane Knoll; Antonio Varcasia; Antonio Scala
Journal:  Parasitol Res       Date:  2021-03-09       Impact factor: 2.289

3.  Efficacy of a single dose of milbemycin oxime/praziquantel combination tablets, Milpro(®), against adult Echinococcus multilocularis in dogs and both adult and immature E. multilocularis in young cats.

Authors:  Dejan Cvejic; Claudia Schneider; Josephus Fourie; Christa de Vos; Stephane Bonneau; Natalia Bernachon; Klaus Hellmann
Journal:  Parasitol Res       Date:  2015-12-11       Impact factor: 2.289

4.  Differential Sensitivity of Myeloid and Lymphoid Cell Populations to Apoptosis in Peritoneal Cavity of Mice with Model Larval Mesocestoides Vogae Infection.

Authors:  T Mačák Kubašková; D Mudroňová; M Gergeľ-Čechová; G Hrčková
Journal:  Helminthologia       Date:  2019-09-01       Impact factor: 1.184

5.  β-Glucan and Parasites.

Authors:  V Vetvicka; R Fernandez-Botran
Journal:  Helminthologia       Date:  2018-07-28       Impact factor: 1.184

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.